Introduction: Macroscopic hematuria is considered a significant risk factor for uro-
| INTRODUCTION
Hemophilia is an inherited deficiency of factor VIII or IX that is associated with recurrent and spontaneous bleeding. People with hemophilia use replacement therapy with clotting factor concentrates to treat bleeding episodes. The most common regimes are on demand, which is episodic replacement therapy in response to an acute bleed, and prophylaxis, which is regular replacement therapy to prevent bleeding. 1 Hematuria is the presence of blood or blood cells in the urine that is either visible (macroscopic) or nonvisible (microscopic). Several underlying conditions may cause hematuria, the most common of which are inflammation or infection of the prostate or bladder, stones, and in older patients, urologic malignancy. 2, 3 In the general male population, reported prevalence of microscopic hematuria ranges from 2.5% 4 to 20% 5 in high-risk patients undergoing urinary dipstick screening for bladder cancer. As even a single episode of macroscopic hematuria is considered a significant risk factor for urologic disease, 6 macroscopic hematuria requires the involvement of several specialists to investigate for an underlying disorder.
To our knowledge, there are few studies of hematuria in people with hemophilia. Two important studies from the 1970s 7, 8 showed that macroscopic hematuria is more prevalent in the hemophilia population than in the general population. Prentice et al 7 examined the underlying renal function and structure in 35 people with hemophilia (age range, 12-60 years) showing that 66% of the patients had a history of either severe or moderate hematuria. In a survey of the renal status in 26 people with hemophilia (age range, 17-82 years), Beck and Evans 8 reported a history of macroscopic hematuria in 69% of the patients. Later studies confirmed the high prevalence of hematuria among people with hemophilia. [9] [10] [11] [12] [13] Although usually considered a benign condition, 14 studies have found macroscopic hematuria associated with a reduction in renal function 15 and an increased risk of hypertension 11 , comorbid conditions that may complicate treatment in aging people with hemophilia.
Previous research has mainly considered hematuria and its association with the development or presence of renal disease and hypertension, and has not assessed the associations between different factor replacement therapies and macroscopic hematuria. As several studies have identified macroscopic hematuria as a risk factor for renal damage, an assessment of treatment that may prevent hematuria is important. Using data from the Age-Related
Developments and Comorbidities in Hemophilia (ADVANCE) Working Group's H3 Study, 12 we examined whether frequent prophylactic factor replacement therapy corresponded with a reduced occurrence of macroscopic hematuria in this large cohort of people with hemophilia.
| MATERIALS AND METHODS

| Data collection
The data set, consisting of 532 men aged 40 years and older, was collected between June 2011 and September 2013 from researchers in 16 participating centers, in 13 European countries and Israel, where
Germany had 3 centers and Italy had 2. The study had an observational, noninterventional, non-product-specific, and cross-sectional design. All data were gathered from consecutive patients attending their routine clinical visit using a case report form and from laboratory data collected no earlier than 1 year prior to the clinical visit.
The case report form included items about patient characteristics, demographics, past and current treatment, and medical history in- to researchers compiling epidemiologic data on the link between hemophilia, hypertension, and hematuria, were included in the study.
Respective national ethical committees or the institutional review boards approved the study.
12,16
| Study design and statistical analyses
In this post hoc analysis, we assessed the association between macroscopic hematuria and treatment, comparing prophylactic treatment to on demand. In contrast to people with moderate or severe hemophilia, almost all individuals with mild hemophilia received on-demand treatment. Therefore, this group could not contribute to explaining the association of interest, and hence only individuals with moderate and severe hemophilia were included in the analysis.
In this paper, we endeavored to provide evidence to answer the following 2 questions:
1. Is frequent prophylactic treatment associated with lower odds of macroscopic hematuria reoccurring in people with hemophilia with a history of macroscopic hematuria?
2. Is frequent long-standing prophylactic treatment associated with a lower number of episodes of macroscopic hematuria?
We conducted 2 separate analyses to answer these questions. In Analysis 1, we analyzed reoccurrence of macroscopic hematuria in the past 5 years. We limited the sample to patients receiving either on-demand or >5 years of prophylactic treatment to know with certainty whether they were on prophylactic therapy for the entire period during which the relevant diagnosis could be set (see Figure 1 for sample selection). To observe an association of prophylaxis with the number of episodes of macroscopic hematuria, it is reasonable to require that the treatment be of a minimum duration. From a clinical perspective, we have considered >15 years of prophylaxis to be long-standing treatment and ≤5 years of treatment to be too short to observe a significant association with number of episodes of macroscopic hematuria.
Therefore, on demand and ≤5 years of treatment together constitute the reference level against which long-standing treatment was compared in Analysis 2 (see Figure 2 for sample selection). We used R version 3.6.0 17 for all analyses, and we considered a 2-tailed P value <0.05 to be statistically significant. 
F I G U R E 1
| Study population
The patients in the study population were 98% white, with median age 51 years (range, 40-98). Of the 370 patients with either moderate or severe hemophilia receiving either on-demand or prophylactic treatment (Level 2 in Figure 1 ), 320 (86.5%) had hemophilia A and 313 (84.6%) had severe disease. Table 1 shows descriptive statistics grouped by severity of hemophilia. The majority of patients with moderate factor deficiency received on-demand therapy, while prophylactic therapy was the most common treatment regime for patients with severe hemophilia. For patients with moderate and severe hemophilia, more than 50% have experienced an episode of macroscopic hematuria, with a higher average number of hematuria episodes in the severe group. Following an episode of macroscopic hematuria, 69% of the patients received factor replacement therapy, 32% were hospitalized, 8.5% required red blood cell transfusion, and 2.5% needed surgery. Twenty-three individuals (6.2%) had inhibitors. Some of them failed treatment with immune tolerance induction, but the majority (82.6%) were never treated. In Germany, the country that recruited most patients, 62% experienced macroscopic hematuria, and among the 60% receiving prophylaxis, 41% had frequent prophylaxis. Austria, Slovenia, and Israel had the highest bleeding rates. Although 73% of patients in Austria used prophylaxis, it appears that frequent treatment is a recent phenomenon. Israel was the country with the highest use of on-demand (79%). Except for 1 patient in Greece, Norway and Sweden had the highest fractions of long-standing frequent prophylaxis, followed by Germany. Table 3 shows results pertaining to the occurrence of macroscopic hematuria obtained from multivariable logistic regressions. In Analysis On average, macroscopic hematuria was more prevalent among individuals with inhibitors. To assess the difference, we reestimated the logistic regression coefficients in Table 3 
| Regression models
| Sensitivity of results to different cutoff values for years of prophylactic treatment
In Analysis 2 in Table 3 , we defined the reference level as individuals who received on-demand or ≤5 years of prophylaxis. We compared this reference level to patients who received >15 years of prophylaxis, the cutoff value we considered long-standing treatment based on clinical experience.
In Table 4 , we examined the robustness of the result for frequent prophylaxis in Table 3 by estimating separate ordinal regression models using the same variables as in Analysis 2 in Table 3 , but with different cutoff values for years of prophylactic treatment. Table 4 shows odds ratios only for the covariate frequent prophylaxis, with rows corresponding to different patient groups included in the reference level and columns corresponding to different cutoff values for duration of prophylaxis treatment. As the TA B L E 1 Descriptive statistics by severity of hemophilia are robust to our specific choice of cutoff in Table 3 . Only when we included all patients on prophylaxis, including those who started <5 years ago, did the effect become statistically insignificant. The strongest effect (lowest OR), highlighted in bold, corresponded to the cutoff choices in Table 3 .
| Frequency vs. number of infusions
In the regression models above, we found that the efficacy of prophylaxis with respect to reducing the risk of macroscopic hematuria depended on the frequency of treatment. It is natural to investigate whether it was the frequency or the number of infusions that constituted the effective treatment. We estimated a linear regression with the reported annual number of infusions as the dependent variable and the reported frequency per week as the independent variable.
We found an almost perfect linear relation with a coefficient approximately equal to 52 with P value <2e −16 . Hence, the 2 measures provide virtually the same information. We have focused on the frequency,
TA B L E 2 Descriptive statistics by on-demand and frequent prophylaxis
Patients with a history of macroscopic hematuria (Analysis 1) All patients (Analysis 2)
On demand
>5 y frequent prophylaxis
On demand & ≤5 y prophylaxis >15 y frequent prophylaxis Note: In Analysis 1, we compared on demand to >5 y of frequent prophylaxis. In Analysis 2, we compared the reference level, defined as on demand and ≤5 y of prophylaxis, to >15 y of frequent prophylaxis. Patients on prophylaxis that was either infrequent or outside of the specified durations were excluded. The numbers in parentheses report the number in the neighboring left column as a fraction of the total number of patients in the corresponding treatment category.
Abbreviations: EGFR, estimated glomerular filtration rate; IQR, interquartile range; NSAIDs, nonsteroidal anti-inflammatory drugs.
TA B L E 3
Association between macroscopic hematuria and prophylactic treatment, adjusting for risk factors Note: This table shows the results from the 2 separate logistic regression models. In Analysis 1, the dichotomous response variable is whether the patient experienced hematuria within the past 5 years. In Analysis 2, the ordinal response variable is the number of macroscopic hematuria episodes. The variables in the first column are the covariates for each model.
Abbreviations: CI, confidence interval; NSAIDs, nonsteroidal antiinflammatory drugs.
as we place greater confidence in patients and physicians correctly reporting frequency than an estimated number of annual infusions.
| DISCUSSION
While different strategies for factor replacement exist, the primary aim in hemophilia treatment is to reduce and treat bleeds. This study found that dosing frequency and duration of prophylactic therapy was associated with fewer episodes of macroscopic hematuria in aging people with hemophilia. Several pediatric studies have recognized the benefits of primary prophylaxis, which is now the preferred treatment for young individuals with hemophilia to prevent joint destruction. 18, 19 Fewer studies exist for the increasing adult hemophilia adults. In contrast, our study included only older people with hemophilia and compared occurrence of macroscopic hematuria for patients receiving different factor replacement therapies.
Our hypothesis was that frequent prophylaxis could prevent episodes of macroscopic hematuria by ensuring higher peak factor levels and increased plasma factor levels for a longer time between treatments. 24 We assumed that an effect from prophylaxis was only In addition to being cytotoxic, heme can promote renal damage by inducing inflammation and fibrosis. 25, 26 Multiple episodes of macroscopic hematuria are associated with a decline in renal function and progression of chronic renal disease. [27] [28] [29] Reducing macroscopic hematuria may thus improve renal function and limit future renal damage. Although management of macroscopic hematuria depends on etiology, the recommended initial treatment is increased fluid intake, either orally or by intravenous hydration.
For persistent macroscopic hematuria, use of factor concentrate is the appropriate treatment.
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TA B L E 4
Association between frequent prophylaxis and number of macroscopic hematuria episodes for varying duration of treatment Abbreviations: CI, confidence interval; OR, odds ratio.
| Limitations
This study has some limitations. We acknowledge that causality cannot be inferred from these cross-sectional data. However, the timeline of certain events is deducible, and we believe associations obtained while considering this can provide important probable evidence. Properly measuring and comparing the outcomes of the 2 treatments, and ensuring no systematic differences among the treatment groups, would require a randomized controlled trial. Since we have no information regarding the reasons for the physician's choice of either on-demand or prophylactic therapy, we cannot rule out bias in the choice of treatment. We can only identify associations between type of treatment and macroscopic hematuria. A possible limitation is that, apart from blood, certain foods and drugs may cause red urine discoloration. We have assumed that patients and physicians have ruled out other probable causes before recording macroscopic hematuria in the case report form. To minimize recall bias, a ratio scale rather than exact numbers was used for the lifetime number of macroscopic hematuria episodes.
Patient reporting was supplemented with information from existing medical records. Although prostate cancer was reported in only 6 patients, 2 of whom were in remission or without relapse, it is a limitation that the case report form did not capture prostate pathology, such as benign hyperplasia, as this condition may be associated with either micro-or macroscopic hematuria. Furthermore, we had no data on patient pharmacokinetic analyses and expected trough levels. On average, prophylaxis treatment was 26.4 units/kg for the total cohort, with 25.3 units/kg for hemophilia A and 33.5 for hemophilia B. However, according to Collins et al 31 , and consistent with our hypothesis, frequency of dosing has a much higher effect on factor trough levels and time per week with increased plasma factor levels than the infused dose. Another limitation was that most data were collected retrospectively. These limitations notwithstanding, the H3 study 12 represents a comprehensive multicountry hemophilia sample that adds to the generalizability of the strong association between frequent prophylaxis and reduction in occurrence of hematuria.
| CONCLUSION
In this study, frequent prophylaxis was negatively associated with occurrence of macroscopic hematuria compared with on-demand.
Infrequent prophylactic treatment had no significant effect. This is in agreement with the current consensus 32 that lifelong prophylactic therapy should be the standard treatment for people with hemophilia (Table S1 ).
